Biophenyx

CRISPR-Select is a cutting-edge technology developed by BioPhenyx that utilizes CRISPR to evaluate the effects of genetic mutations, providing reliable insights into drug targets and patient responses. BioPhenyx helps our customers determine drug targets and drug responses in a multitude of settings from the earliest target discovery to patient response to therapeutics. Exceptional data on the role of molecular targets in disease etiology and their responsiveness to drug candidates are critical for better development of therapeutics. This will reduce attrition rates in development programs and clinical trials. The BioPhenyx team has invented and developed the CRISPR-Select technology to generate unmatched data quality. We perform precise, fast (weeks), and quantitative analysis of a candidate drug target or a drug response in cells, where we introduce mutation(s) needed to address the question. This is done with no need for cell line generation and clonal selection.